Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01936/full |
id |
doaj-2dc722a1ea5e4e479626074372fc58f4 |
---|---|
record_format |
Article |
spelling |
doaj-2dc722a1ea5e4e479626074372fc58f42020-11-24T23:39:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-01-01810.3389/fimmu.2017.01936313558Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific TargetsCarlos Cuesta-Mateos0Carlos Cuesta-Mateos1Ana Alcaraz-Serna2Beatriz Somovilla-Crespo3Cecilia Muñoz-Calleja4Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, SpainIMMED S.L., Immunological and Medicinal Products, Madrid, SpainServicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, SpainDepartment of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, SpainServicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, SpainToday, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-specific antigens (LSAs) have been successfully developed. Non-LSAs (NLSAs) are molecules that are not restricted to specific leukocyte subsets or tissues but play relevant pathogenic roles in blood cancers including the development, proliferation, survival, and refractoriness to therapy of tumor cells. In consequence, efforts to target NLSAs have resulted in a plethora of mAbs—marketed or in development—to achieve different goals like neutralizing oncogenic pathways, blocking tumor-related chemotactic pathways, mobilizing malignant cells from tumor microenvironment to peripheral blood, modulating immune-checkpoints, or delivering cytotoxic drugs into tumor cells. Here, we extensively review several novel mAbs directed against NLSAs undergoing clinical evaluation for treating hematological malignancies. The review focuses on the structure of these antibodies, proposed mechanisms of action, efficacy and safety profile in clinical studies, and their potential applications in the treatment of hematological malignancies.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01936/fullmonoclonal antibodyimmunotherapyhematological malignanciesnon-lineage antigensmechanism of action |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carlos Cuesta-Mateos Carlos Cuesta-Mateos Ana Alcaraz-Serna Beatriz Somovilla-Crespo Cecilia Muñoz-Calleja |
spellingShingle |
Carlos Cuesta-Mateos Carlos Cuesta-Mateos Ana Alcaraz-Serna Beatriz Somovilla-Crespo Cecilia Muñoz-Calleja Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets Frontiers in Immunology monoclonal antibody immunotherapy hematological malignancies non-lineage antigens mechanism of action |
author_facet |
Carlos Cuesta-Mateos Carlos Cuesta-Mateos Ana Alcaraz-Serna Beatriz Somovilla-Crespo Cecilia Muñoz-Calleja |
author_sort |
Carlos Cuesta-Mateos |
title |
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
title_short |
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
title_full |
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
title_fullStr |
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
title_full_unstemmed |
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
title_sort |
monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2018-01-01 |
description |
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-specific antigens (LSAs) have been successfully developed. Non-LSAs (NLSAs) are molecules that are not restricted to specific leukocyte subsets or tissues but play relevant pathogenic roles in blood cancers including the development, proliferation, survival, and refractoriness to therapy of tumor cells. In consequence, efforts to target NLSAs have resulted in a plethora of mAbs—marketed or in development—to achieve different goals like neutralizing oncogenic pathways, blocking tumor-related chemotactic pathways, mobilizing malignant cells from tumor microenvironment to peripheral blood, modulating immune-checkpoints, or delivering cytotoxic drugs into tumor cells. Here, we extensively review several novel mAbs directed against NLSAs undergoing clinical evaluation for treating hematological malignancies. The review focuses on the structure of these antibodies, proposed mechanisms of action, efficacy and safety profile in clinical studies, and their potential applications in the treatment of hematological malignancies. |
topic |
monoclonal antibody immunotherapy hematological malignancies non-lineage antigens mechanism of action |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01936/full |
work_keys_str_mv |
AT carloscuestamateos monoclonalantibodytherapiesforhematologicalmalignanciesnotjustlineagespecifictargets AT carloscuestamateos monoclonalantibodytherapiesforhematologicalmalignanciesnotjustlineagespecifictargets AT anaalcarazserna monoclonalantibodytherapiesforhematologicalmalignanciesnotjustlineagespecifictargets AT beatrizsomovillacrespo monoclonalantibodytherapiesforhematologicalmalignanciesnotjustlineagespecifictargets AT ceciliamunozcalleja monoclonalantibodytherapiesforhematologicalmalignanciesnotjustlineagespecifictargets |
_version_ |
1725514958859403264 |